Última actualización :
19/11/2024
Los equipos de investigación - Universidad Complutense de Madrid,Facultad de Farmacia   pdf  
España
universidad
Universidad Complutense de Madrid,Facultad de Farmacia
Madrid
Bibliografía   Bibliografía   (12)  
1
Stability of daptomycin reconstituted vials and infusion solutions.
Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. (sanchez@salud.madrid.org)
EJHP - 2018 - ; 25: 107-110.
2
Stability of carboplatin infusion solutions used in desensitization protocol.
Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. (rovazsan@hotmail.com)
J Oncol Pharm Practice - 2018 - 25,5:1076?1081
3
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine.
Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. ()
J Palliat Med - 2010 - ; 13, 3: 273-277.
4
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. (ebarcia@farm.ucm.es)
Support Care Cancer - 2007 - ; 15: 57-62.
5
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients.
Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B. (soneal@farm.ucm.es)
J Clin Pharm Ther - 2007 - ; 32: 441-444.
6
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients.
Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. (soneal@farm.ucm.es )
Int J Pharm - 2006 - ; 307: 278-284.
7
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.
Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E. ( soneal@farm.ucm.es)
Arzneimittel Forschung - 2006 - ; 56, 10: 714-720.
8
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.
Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. ()
Support Care Cancer - 2005 - ; 13, 4: 239-245.
9
Stability of tramadol and haloperidol for continuous infusion at home.
Negro S, Martin A, Azuara ML, Sanchez Y, Barcia E. ()
J Pain Symptom Manage - 2005 - ; 30: 192-199.
10
Stability study of an aqueous formulation of captopril at 1 mg/ml.
Escribano Garcia MJ, Torrado Duran S, Torrado Duran JJ. (torrado2@farm.ucm.es)
Farm Hosp - 2005 - ; 29: 30-36.
11
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. ()
Support Care Cancer - 2003 - ; 11, 2: 107-113.
12
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Azuara ML, Sanchez Y, Reyes R, Barcia E. (soneal @eucmax.sim.ucm.es)
Support Care Cancer - 2001 -

Lista de la molécula   moléculas estudiadas   (11)  
Antihipertensor Solución Oral Captopril
fármacos contra el cáncer Inyectables Carboplatin
Antibiótico Inyectables Daptomycin
Antiinflamatorio Inyectables Dexamethasone sodium phosphate
Diurético Inyectables Furosemide
Neuroléptico Inyectables Haloperidol lactate
Antiemético Inyectables Metoclopramide hydrochloride
Ansiolítico Inyectables Midazolam hydrochloride
Antálgico Inyectables Morphine hydrochloride
Antimuscarínico Inyectables Scopolamine N-butyl bromide
Antálgico Inyectables Tramadol hydrochloride

  Mentions Légales